MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2018 International Congress

    Impact of STN-DBS on Medication Reduction

    M. Carmona-Abellán, G. de Ulibarri, J. Guridi, P. Clavero, M. Alegre, R. Luquin-Piudo (Pamplona, Spain)

    Objective: We aim to evaluate the efficacy of subthalamic nucleus deep brain stimulation on reducing medication in Parkinson´s disease patients. Background: Parkinson's disease (PD) is…
  • 2018 International Congress

    Presynaptic dopamine depletion determines the timing of levodopa-induced dyskinesia onset in Parkinson’s disease

    HS. Yoo, SJ. Chung, BS. Ye, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

    Objective: To investigated whether dopaminergic function in the nigrostriatal system is associated with the timing of levodopa-induced dyskinesia (LID) onset in Parkinson's disease (PD). Background:…
  • 2018 International Congress

    Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period

    A. Azimov, R. Sadykov, G. Rakhimbaeva, F. Azimov (Tashkent, Uzbekistan)

    Objective: To study the possibility of using dopaminergic medicines for the treatment of Bell`s paralysis in acute period. Background: In previous reports we conjectured that…
  • 2018 International Congress

    Study On Patient- And Caregiver-Reported Symptoms And Outcomes With Levodopa-Carbidopa Intestinal Gel For The Treatment Of Advanced Parkinson’s Disease. ADEQUA Study

    F. Valldeoriola, M.J. Catalán, F. Escamilla-Sevilla, E. Freire, J. Olivares, E. Cubo, D. Santos, J.C. Parra, G. Arroyo, J.M. Arbelo (Barcelona, Spain)

    Objective: The primary objective of the present study was to assess the effect of levodopa-carbidopa intestinal gel (LCIG) on the QoL of patients with advanced…
  • 2018 International Congress

    Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)

    M. Lin, R. Laureno (Washington, DC, USA)

    Objective: To evaluate whether levodopa induced dyskinesia is preventable in the treatment of patients with Parkinson’s disease. Background: Dyskinesia is one of the major complications…
  • 2018 International Congress

    Economic burden of advanced Parkinson’s disease in a national sample of elderly US Medicare beneficiaries: A prevalence-based estimate

    N. Dahodwala, P. Li, J. Jahnke, V. Ladage, P. Kandukuri, J. Zamudio, Y. Bao, Y. Jalundhwala, J. Doshi (Philadelphia, PA, USA)

    Objective: To estimate Parkinson's Disease (PD)-related health care costs in a national sample of elderly patients in the US and examine the incremental cost burden…
  • 2018 International Congress

    Higher motor cortex connectivity with subthalamic stimulation than with levodopa: A resting state fMRI study in Parkinson’s disease

    R. Jech, K. Mueller, F. Růžička, Š. Holiga, T. Ballarini, O. Bezdicek, H. Möller, J. Vymazal, E. Růžička, L. Schroeter, D. Urgošík (Prague, Czech Republic)

    Objective: To perform a direct comparison between the effect of levodopa medication and deep brain stimulation of the subthalamic nucleus (STN DBS) on functional brain…
  • 2018 International Congress

    Clinical practice of levodopa in parkinsonism

    AC. Chen (Taichung, Taiwan)

    Objective: This study is for the clinical effect of levodopa in parkinsonism. Background: Levodopa was common used in Parkinson disease. Levodopa induced dyskinesia(LID) is the…
  • 2018 International Congress

    Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease

    C. Sung, M. Danoudis, R. Iansek (Melbourne, Australia)

    Objective: To investigate the effectiveness of Levodopa carbidopa ascorbic acid solution (LCAS) in reducing the severity of bradykinesia and dyskinesia in advanced Parkinson’s disease (PD).…
  • 2018 International Congress

    Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients

    J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, D. Georgescu, J. Szederjesi, I. Mihaly, S. Szatmari (Tirgu Mures, Romania)

    Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral,…
  • « Previous Page
  • 1
  • …
  • 39
  • 40
  • 41
  • 42
  • 43
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Determinants of quality of life in a large, online cohort of patients with Parkinson’s disease
  • Defining minimal clinically important differences in Huntington’s disease: An anchor-based approach
  • DaTscan in clinical evaluation of Multiple System Atrophy
  • #25179 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley